White Paper on cost implications of Leqembi and other anti-amyloid drugs for payers and ACOs and options for utilization management
Introduction: The recent full approval of Lecanemab (Leqembi) by the FDA has ushered in a new era in the treatment of Alzheimer’s disease. As the first disease-modifying treatment to receive such approval, Leqembi offers hope to patients with early-stage Alzheimer’s. However, its adoption poses cost implications for payers and risk-bearing health systems. In a newly …
